_recent-advances-in-advanced-breast-cancer.jpg "Recent advances in advanced breast cancer from everolimus chemotherapy Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 18 min 30 sec
✓ Published: 19-Jan-2018
✓ Published: 19-Jan-2018
Description:
Prof Stephen Johnston – Royal Marsden Hospital, UK; Adjunct Prof Johanna Mattson - Helsinki University Central Hospital, Finland; Prof Ahmad Awada, Jules Bordet Institute, Belgium; Prof Rob Coleman - Weston Park Hospital, UK:nnnThe BOLERO (Breast Cancer Trials of Oral Everolimus) clinical trial is a study which assessed the use of the mTOR inhibitor everolimus in combination with exemestane as way to overcome endocrine resistance in breast cancer patients. Early results of this trial have show
Prof Stephen Johnston – Royal Marsden Hospital, UK; Adjunct Prof Johanna Mattson - Helsinki University Central Hospital, Finland; Prof Ahmad Awada, Jules Bordet Institute, Belgium; Prof Rob Coleman - Weston Park Hospital, UK:nnnThe BOLERO (Breast Cancer Trials of Oral Everolimus) clinical trial is a study which assessed the use of the mTOR inhibitor everolimus in combination with exemestane as way to overcome endocrine resistance in breast cancer patients. Early results of this trial have show
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_managing-mouth-sores-from-everolimus-in-breast-cancer.webp "OncLiveTV")
_recent-advances-in-advanced-breast-cancer.webp "Prof Stephen Johnston – Royal Marsden Hospital, UK; Adjunct Prof Johanna Mattson - Helsinki University Central Hospital, Finland; Prof Ahmad Awada, Jules Bordet Institute, Belgium; Prof Rob Coleman - Weston Park Hospital, UK:nnnThe BOLERO (Breast Cancer Trials of Oral Everolimus) clinical trial is a study which assessed the use of the mTOR inhibitor everolimus in combination with exemestane as way to overcome endocrine resistance in breast cancer patients. Early results of this trial have show")
_integration-of-radiotherapy-in-muscle-invasive-bladder-cancer.webp "UBC Urology Rounds")
_winship-grand-rounds-july-19-2017-mehmet-asim-bilen-md.webp "Winship Cancer Institute of Emory University")
_everolimus-zortress-prescription-medication-instructions-for-post-transplant-patients.webp "Barnes-Jewish Hospital")
⏲ 3 minutes 30 seconds 👁 607
_does-treatment-with-everolimus-octreotide-lar-affect-5-hiaa-levels-in-patients-with-advanced-nets.webp "Oncology.TV")
Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NETs?
⏲ 8 minutes 51 seconds 👁 516
_update-11-neuroendocrine-tumors.webp "HMP Education")
_real-world-efficacy-of-everolimus-exemestane-hr-her2-bc.webp "VJOncology")
_managing-mouth-sores-from-everolimus-in-breast-cancer.jpg)
_integration-of-radiotherapy-in-muscle-invasive-bladder-cancer.jpg)
_winship-grand-rounds-july-19-2017-mehmet-asim-bilen-md.jpg)
_everolimus-zortress-prescription-medication-instructions-for-post-transplant-patients.jpg)
_does-treatment-with-everolimus-octreotide-lar-affect-5-hiaa-levels-in-patients-with-advanced-nets.jpg)
_update-11-neuroendocrine-tumors.jpg)
_real-world-efficacy-of-everolimus-exemestane-hr-her2-bc.jpg)
![[+]](/images/menu.gif){kind=small}